Kao-Ping Chua1, Chin Hwa Y Dahlem2, Thuy D Nguyen3, Chad M Brummett4, Rena M Conti5, Amy S Bohnert6, Aaron D Dora-Laskey7, Keith E Kocher8. 1. Department of Pediatrics, Susan B. Meister Child Health Evaluation and Research Center, University of Michigan, Ann Arbor, MI; Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI. Electronic address: chuak@med.umich.edu. 2. Department of Health Behavior and Biological Sciences, University of Michigan School of Nursing, Ann Arbor, MI. 3. Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI. 4. Department of Anesthesiology, University of Michigan School of Medicine, Ann Arbor, MI; Michigan Opioid Prescribing Engagement Network, Institute for Healthcare Policy and Innovation, Ann Arbor, MI. 5. Department of Markets, Public Policy, and Law, Institute for Health System Innovation and Policy, Questrom School of Business, Boston University, Boston, MA. 6. Department of Anesthesiology, University of Michigan School of Medicine, Ann Arbor, MI; VA Center for Clinical Management Research, VA Ann Arbor Health System, Ann Arbor, MI. 7. Department of Emergency Medicine, Michigan State University College of Human Medicine, East Lansing, MI. 8. Department of Emergency Medicine and Department of Learning Health Sciences, University of Michigan School of Medicine, Ann Arbor, MI; VA Center for Clinical Management Research, VA Ann Arbor Health System, Ann Arbor, MI.
Abstract
STUDY OBJECTIVE: Nonfatal emergency department (ED) visits for opioid overdose are important opportunities to prescribe naloxone and buprenorphine, both of which can prevent future overdose-related mortality. We assessed the rate of this prescribing using national data from August 2019 to April 2021, a period during which US opioid overdose deaths reached record levels. METHODS: We conducted a retrospective cohort analysis using Symphony Health's Integrated Dataverse, which includes data from 5,800 hospitals and 70,000 pharmacies. Of ED visits for opioid overdose between August 4, 2019, and April 3, 2021, we calculated the proportion with at least 1 naloxone prescription within 30 days and repeated this analysis for buprenorphine. To contextualize the naloxone prescribing rate, we calculated the proportion of ED visits for anaphylaxis with at least 1 prescription for epinephrine-another life-saving rescue medication-within 30 days. RESULTS: Analyses included 148,966 ED visits for opioid overdose. Mean weekly visits increased 23.6% during the period between April 26, 2020 and October 3, 2020 compared with the period between August 4, 2019 to April 25, 2020. Visits declined to prepandemic levels between October 4, 2020 and March 13, 2021, after which visits began to rise. Naloxone and buprenorphine were prescribed within 30 days at 7.4% and 8.5% of the 148,966 visits, respectively. The naloxone prescribing rate (7.4%) was substantially lower than the epinephrine prescribing rate (48.9%) after ED visits for anaphylaxis. CONCLUSION: Between August 4, 2019, and April 3, 2021, naloxone and buprenorphine were only prescribed after 1 in 13 and 1 in 12 ED visits for opioid overdose, respectively. Findings suggest that clinicians are missing critical opportunities to prevent opioid overdose-related mortality.
STUDY OBJECTIVE: Nonfatal emergency department (ED) visits for opioid overdose are important opportunities to prescribe naloxone and buprenorphine, both of which can prevent future overdose-related mortality. We assessed the rate of this prescribing using national data from August 2019 to April 2021, a period during which US opioid overdose deaths reached record levels. METHODS: We conducted a retrospective cohort analysis using Symphony Health's Integrated Dataverse, which includes data from 5,800 hospitals and 70,000 pharmacies. Of ED visits for opioid overdose between August 4, 2019, and April 3, 2021, we calculated the proportion with at least 1 naloxone prescription within 30 days and repeated this analysis for buprenorphine. To contextualize the naloxone prescribing rate, we calculated the proportion of ED visits for anaphylaxis with at least 1 prescription for epinephrine-another life-saving rescue medication-within 30 days. RESULTS: Analyses included 148,966 ED visits for opioid overdose. Mean weekly visits increased 23.6% during the period between April 26, 2020 and October 3, 2020 compared with the period between August 4, 2019 to April 25, 2020. Visits declined to prepandemic levels between October 4, 2020 and March 13, 2021, after which visits began to rise. Naloxone and buprenorphine were prescribed within 30 days at 7.4% and 8.5% of the 148,966 visits, respectively. The naloxone prescribing rate (7.4%) was substantially lower than the epinephrine prescribing rate (48.9%) after ED visits for anaphylaxis. CONCLUSION: Between August 4, 2019, and April 3, 2021, naloxone and buprenorphine were only prescribed after 1 in 13 and 1 in 12 ED visits for opioid overdose, respectively. Findings suggest that clinicians are missing critical opportunities to prevent opioid overdose-related mortality.
Authors: Kathryn Hawk; Jason Hoppe; Eric Ketcham; Alexis LaPietra; Aimee Moulin; Lewis Nelson; Evan Schwarz; Sam Shahid; Donald Stader; Michael P Wilson; Gail D'Onofrio Journal: Ann Emerg Med Date: 2021-06-22 Impact factor: 5.721
Authors: Kristin M Holland; Christopher Jones; Alana M Vivolo-Kantor; Nimi Idaikkadar; Marissa Zwald; Brooke Hoots; Ellen Yard; Ashley D'Inverno; Elizabeth Swedo; May S Chen; Emiko Petrosky; Amy Board; Pedro Martinez; Deborah M Stone; Royal Law; Michael A Coletta; Jennifer Adjemian; Craig Thomas; Richard W Puddy; Georgina Peacock; Nicole F Dowling; Debra Houry Journal: JAMA Psychiatry Date: 2021-04-01 Impact factor: 21.596
Authors: Joanna G Katzman; Mikiko Y Takeda; Nina Greenberg; Monica Moya Balasch; Amal Alchbli; William G Katzman; Julie G Salvador; Snehal R Bhatt Journal: JAMA Netw Open Date: 2020-02-05
Authors: Elizabeth M Schoenfeld; Lauren M Westafer; Samantha A Beck; Benjamin G Potee; Sravanthi Vysetty; Caty Simon; Jillian M Tozloski; Abigail L Girardin; William E Soares Journal: Acad Emerg Med Date: 2022-05-16 Impact factor: 5.221
Authors: Tiffany Champagne-Langabeer; Marylou Cardenas-Turanzas; Irma T Ugalde; Christine Bakos-Block; Angela L Stotts; Lisa Cleveland; Steven Shoptaw; James R Langabeer Journal: Children (Basel) Date: 2022-04-07
Authors: Maria A Stevens; Jennifer Tsai; Samuel T Savitz; Bidisha Nath; Edward R Melnick; Gail D'Onofrio; Molly Moore Jeffery Journal: JAMA Netw Open Date: 2022-06-01